Key Highlights

• DBV Technologies issued a press release on June 29, 2026, attaching the document as Exhibit 99.1.

• The company is working with regulators to refine its submission approach for the VIASkin Peanut Patch.

• A focus remains on addressing the needs of young children with peanut allergy through a transdermal delivery method.

DBV Technologies (NYSE: DBVT) provided an update on June 29, 2026, regarding its progress toward a potential biologics license application (BLA) for the VIASkin Peanut Patch, a treatment designed for pediatric patients with peanut allergy. The announcement reflects the company’s ongoing efforts to advance its regulatory strategy.

Press Release Details

The company’s disclosure included a press release, attached as Exhibit 99.1, which outlined its current regulatory activities. The filing adheres to U.S. Securities reporting requirements, ensuring transparency for stakeholders.

Regulatory Engagement

DBV Technologies has been in discussions with regulatory authorities to clarify expectations and streamline the path toward a potential submission. These interactions aim to address key considerations ahead of any formal application, supporting a more efficient review process.

Clinical Focus

The VIASkin Peanut Patch is being developed as a non-oral option for young children, a group where peanut allergy management remains a significant challenge. The patch-based approach is intended to provide an alternative to traditional methods, potentially reducing risks associated with other forms of exposure.

Development Timeline

The company is working to finalize its submission strategy, with a focus on meeting regulatory standards. While no specific filing date was confirmed, the update signals continued progress in preparing the necessary documentation.

Sector Context

The development of pediatric allergy treatments has drawn attention from investors and healthcare professionals, given the limited number of approved options in this space. DBV Technologies’ efforts could contribute to broader advancements in allergy management, particularly for younger patients. The company’s progress may also influence discussions around innovation in transdermal therapies for food allergies.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.